Evidence map›Paper›PMID 28667080›Full record

Trial reportJournal of the American Society of Nephrology : JASN2017

A Randomized Trial of Vitamin D Supplementation on Vascular Function in CKD.

Vivek Kumar, Ashok Kumar Yadav, Anupam Lal, Vinod Kumar, Manphool Singhal, Laurent Billot, Krishan Lal Gupta, Debasish Banerjee, Vivekanand Jha

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Overview of results from the Vitamin D Assessment (ViDA) study.Journal of endocrinological investigation · 2019
    Trial
  12. Trial
  13. Trial
  14. Review
  15. Article
  16. The role of nutritional vitamin D in chronic kidney disease-mineral and bone disorder in children and adults with chronic kidney disease, on dialysis, and after kidney transplantation-a European consensus statement.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Article
  17. Vitamin D: are all compounds equal?Clinical kidney journal · 2025
    Article
  18. Review
  19. Review
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Vivek KumarDepartments of Nephrology and.
Ashok Kumar YadavDepartments of Nephrology and.
Anupam LalRadiodiagnosis, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Vinod KumarDepartments of Nephrology and.
Manphool SinghalRadiodiagnosis, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Laurent BillotGeorge Institute for Global Health, Sydney, New South Wales, Australia.
Krishan Lal GuptaDepartments of Nephrology and.
Debasish BanerjeeRenal and Transplantation Unit, St. George's University Hospitals National Health Service Foundation Trust, London, UK.
Vivekanand JhaDepartments of Nephrology and vjha@pginephro.org.

Funding

British Heart Foundation PG/10/71/28462
6 · The paper itself

Abstract

Vitamin D deficiency associates with mortality in patients with CKD, and vitamin D supplementation might mitigate cardiovascular disease risk in CKD. In this randomized, double-blind, placebo-controlled trial, we investigated the effect of cholecalciferol supplementation on vascular function in 120 patients of either sex, aged 18-70 years, with nondiabetic CKD stage 3-4 and vitamin D deficiency (serum 25-hydroxyvitamin D ≤20 ng/ml). We randomized patients using a 1:1 ratio to receive either two directly observed oral doses of cholecalciferol (300,000 IU) or matching placebo at baseline and 8 weeks. The primary outcome was change in endothelium-dependent brachial artery flow-mediated dilation at 16 weeks. Secondary outcome measures included changes in pulse wave velocity and circulating biomarkers. Cholecalciferol supplementation significantly increased endothelium-dependent brachial artery flow-mediated dilation at 16 weeks, whereas placebo did not (between-group difference in mean change: 5.49%; 95% confidence interval, 4.34% to 6.64%;

Indexed as

AdultBiomarkersCardiovascular DiseasesC-Reactive ProteinDietary SupplementsEndothelium, VascularFemaleHumansInterleukin-6MaleMiddle AgedPulse Wave AnalysisRenal Insufficiency, ChronicVascular StiffnessVasodilationVitamin DBiomarkersC-Reactive ProteinInterleukin-6Vitamin DVitaminscardiovascular diseasechronic kidney diseaseVitamin D

Identifiers

PMID28667080
PMCPMC5619968

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.